Compare SDGR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | ARDX |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2014 |
| Metric | SDGR | ARDX |
|---|---|---|
| Price | $15.03 | $5.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $21.00 | $15.14 |
| AVG Volume (30 Days) | 1.4M | ★ 4.7M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | $2,607,000.00 |
| Revenue This Year | $0.76 | $37.75 |
| Revenue Next Year | $4.60 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $4.08 |
| 52 Week High | $23.02 | $8.40 |
| Indicator | SDGR | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 37.18 |
| Support Level | $11.27 | $4.95 |
| Resistance Level | $16.47 | $5.34 |
| Average True Range (ATR) | 0.77 | 0.19 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 7.56 | 16.38 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.